- Arbele has entered partnerships with BioAI Health and Chime Biologics to accelerate the development of immunotherapies for cancer treatment.
- The collaborations focus on AI-powered diagnostics and drug manufacturing to ensure smoother clinical trial progress.
Arbele, a biopharmaceutical company focusing on cadherin-17 (CDH17), has announced strategic partnerships in precision oncology aimed at advancing immunotherapeutics. These collaborations, involving BioAI Health and Chime Biologics, are expected to enhance the development of bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs) for cancer treatment.
The first partnership, with BioAI Health, focuses on using artificial intelligence (AI) to develop a quantification algorithm for CDH17 expression in tumor tissues. The goal is to create a companion diagnostic test for colorectal cancer (CRC) therapies, using BioAI’s PredictX platform to analyse Arbele’s clinical trial data. This AI-driven approach could improve patient selection and predict clinical outcomes. Dr. John Luk, CEO of Arbele, noted, “This collaboration is a critical step in guiding us to the right treatment modalities and improving outcomes for patients with high-mortality cancers.”
The second partnership, with Chime Biologics, aims to accelerate chemistry, manufacturing, and control (CMC) process development for ADCs and TCEs. Chime will support Arbele’s pipeline of approximately 10 immunotherapeutics, with the first anti-CDH17 ADC expected to file for investigational new drug (IND) submission in early 2025. Chime Biologics President, Dr. Jimmy Wei, highlighted their Quality-by-Design (QbD) strategy, aimed at ensuring cost-effective development and global accessibility of innovative treatments.
